Stockscreener 앱 받기
1.79
0.56%
0.01
시간 외 거래:
1.79
전일 마감가:
$1.78
열려 있는:
$1.78
하루 거래량:
7,786
Relative Volume:
0.24
시가총액:
$65.02M
수익:
$134.00K
순이익/손실:
$-9.93M
주가수익비율:
-4.8378
EPS:
-0.37
순현금흐름:
$-6.72M
1주 성능:
-5.29%
1개월 성능:
-4.28%
6개월 성능:
-17.13%
1년 성능:
+192.05%
1일 변동 폭
$1.78
$1.82
1주일 범위
$1.77
$1.9357
52주 변동 폭
$0.52
$3.35
Entera Bio Ltd Stock (ENTX) Company Profile
명칭
Entera Bio Ltd
전화
972-2-532-7151
주소
KIRYAT HADASSAH, MINRAV BUILDING, JERUSALEM
Entera Bio Ltd Stock (ENTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-03-22 | 개시 | Aegis Capital | Buy |
Entera Bio Ltd 주식(ENTX)의 최신 뉴스
Short Interest in Entera Bio Ltd. (NASDAQ:ENTX) Drops By 14.4% - MarketBeat
Entera Bio Ltd. (NASDAQ:ENTX) Short Interest Up 38.4% in September - MarketBeat
Entera Bio outlook steady as H.C. Wainwright backs potential of total hip BMD in osteoporosis care - Investing.com Australia
Entera Bio (NASDAQ:ENTX) Rating Reiterated by HC Wainwright - MarketBeat
Are Medical Stocks Lagging Argenx (ARGX) This Year? - Yahoo Finance
ENTX & OPK Stock May Gain Following Positive PK/PD Research Data - MSN
Entera Bio shares hold Buy rating on OXM study success By Investing.com - Investing.com Australia
Entera Bio shares hold Buy rating on OXM study success - Investing.com
Entera Bio's (ENTX) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Entera Bio and OPKO Health report promising obesity treatment study By Investing.com - Investing.com Australia
Entera Bio and OPKO Health report promising obesity treatment study - Investing.com
Entera Bio And Opko Health Provide Update On Pk/Pd Results Of Oral Oxyntomodulin (Glp-1/Glucagon) Peptide Tablet Candidate For Obesity And Metabolic Disorders - XM
Entera Bio and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide - EIN News
Is Entera Bio (ENTX) Stock Outpacing Its Medical Peers This Year? - MSN
Is Entera Bio (ENTX) Outperforming Other Medical Stocks This Year? - MSN
Entera Bio Ltd. (NASDAQ:ENTX) Sees Significant Increase in Short Interest - MarketBeat
We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate - Yahoo Finance
Entera Bio to Participate in Upcoming Investor and Scientific Conferences - GlobeNewswire
All You Need to Know About Entera Bio (ENTX) Rating Upgrade to Buy - Yahoo Finance
Entera Bio Ltd. Forecasted to Earn Q3 2024 Earnings of ($0.05) Per Share (NASDAQ:ENTX) - Defense World
Entera Bio Ltd. to Post Q3 2024 Earnings of ($0.05) Per Share, HC Wainwright Forecasts (NASDAQ:ENTX) - MarketBeat
Entera Bio Ltd. (NASDAQ:ENTX) Short Interest Down 51.0% in July - MarketBeat
Entera Bio (NASDAQ:ENTX) Releases Earnings Results - MarketBeat
Entera Bio's (ENTX) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
HC Wainwright Reiterates Buy Rating for Entera Bio (NASDAQ:ENTX) - Defense World
Entera Bio Reports Q2 2024 Financial Results and Provides Business Updates - GlobeNewswire
Virtu Financial LLC Invests $37,000 in Entera Bio Ltd. (NASDAQ:ENTX) - Defense World
Entera Bio Ltd expected to post a loss of 6 cents a shareEarnings Preview - XM
The 10 Best Biotech Stocks Under $5 To Buy For September 2024! - The Stock Dork
Entera Bio shareholders approve executive compensation, board appointments - Investing.com
Entera’s EB613, the First Once Daily PTH(1-34) Tablet Treatment Dedicated to Post-Menopausal Women with High Risk Osteoporosis Abstract Selected for Presentation at the ASBMR 2024 Annual MeetingKey SABRE Update Also Expected - StockTitan
Entera Bio (NASDAQ:ENTX) Trading Up 1.9% - MarketBeat
Entera Bio (NASDAQ:ENTX) Stock Price Up 1.9% - Defense World
Entera Bio (NASDAQ:ENTX) & Vericel (NASDAQ:VCEL) Financial Survey - Defense World
Short bowel syndrome Market Positive Outlook: Phase Bio , Orphan Technologies , Zealand Pharma - Newstrail
3 Meme Stocks to Buy and Hold for Potential 300% Returns in 3 Years - Markets Insider
Entera Bio (NASDAQ:ENTX) Trading 6% Higher - MarketBeat
Entera Bio (NASDAQ:ENTX) Stock Price Up 6% - Defense World
Entera Bio Announces Execution of Key Regulatory Milestones for EB613, the First Oral Anabolic Drug Proposed for ... - Barchart
Rags to Riches: 3 Penny Stocks That Could Make Early Investors Rich - Markets Insider
Head to Head Contrast: Entera Bio (NASDAQ:ENTX) and HilleVax (NASDAQ:HLVX) - Defense World
Aegis Capital initates Entera Bio Ltd (ENTX) rating to a Buy – Knox Daily - Knox Daily
Entera Bio Ltd (ENTX)'s stock rises to 2.11 per share – US Post News - US Post News
Entera Bio Ltd. (ENTX) Reports Q1 Loss, Misses Revenue Estimates - Yahoo New Zealand News
Entera Bio (ENTX) to Report Q4 Earnings: What's in the Cards? - Yahoo Lifestyle Singapore
Under-$10 Picks: 3 Biotech Stocks That Can Double Before the End of 2024 - Markets Insider
Meme Mania Meets Medicine: 3 Biotech Stocks Primed to Soar - Yahoo Finance
Entera Bio Ltd (ENTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Entera Bio Ltd 주식 (ENTX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Taitel Haya | Director |
Jan 10 '24 |
Buy |
0.77 |
7,615 |
5,864 |
25,615 |
| LIEBERMAN GERALD M | Director |
Dec 22 '23 |
Buy |
0.71 |
23,952 |
17,006 |
226,961 |
| Toledano Miranda Jayne | Chief Executive Officer |
Dec 22 '23 |
Buy |
0.71 |
23,952 |
17,006 |
110,752 |
2.02%
0.47%
자본화:
|
볼륨(24시간):